GenKyoTex, PsiOxus Raise VC Funding In Europe To Reach Phase II POC
This article was originally published in The Pink Sheet Daily
Executive Summary
GenKyoTex's first-in-class NOX inhibitors and PsiOxus's oncolytic viruses attract funding from European VCs to cross "death valley."
You may also be interested in...
Start-Up Quarterly Statistics, Q3 2012
In the third quarter of 2012, start-up companies raised a total of $682 million across all industries, roughly 19% more than in the previous quarter. Of that money, 65% went to biopharmas. Several large molecule-focused companies inked deals during Q3. Four start-ups were acquired – three biopharmas and one medical device company.
Financings Of The Fortnight: Secondary Offerings Up From Pace Set In 2010 And 2011
Plus news on recent financings by Genkyotex, Synageva, Nektar Therapeutics and Edmond de Rothschild Investment Partners.
Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal
Venture investors who saw the company through a failed IPO attempt receive long-awaited returns from a $425 million upfront payment.